Blog del Instituto de Microdosificación

This is the fourth publication on the administration of a microdose of LSD (5, 10, or 20µg). The double-blind, placebo-controlled study (n=24) found enhanced attention, slower information processing, more positive mood, and increased anxiety and confusion. Again, the results are small and ambiguous.

A placebo-controlled within-subject study including, 24 healthy participants, was conducted to assess the acute effects of three LSD doses (5, 10, and 20 mcg) on measures of cognition, mood, and subjective experience.

This qualitative study (n=198) of opinions on microdosing found that they were generally well-tolerated and were used for therapeutic or enhancement purposes. The study analysed 32 videos and the self-report reactions to those videos.

This survey study (n=525) found that the motivation for microdosing (psilocybin and LSD) was mainly to improve mental health, personal development, and cognitive enhancement. Four out of five participants used one or more harm reduction techniques on microdosing days (e.g. not dosing when unwell, no alcohol, avoiding driving).

This prospective survey study (n=81) found that expectancy effects were mostly predictive of microdosing outcomes on reductions in state anxiety, depressive symptoms (at 4-week endpoint), and positive outcomes (e.g. psychological resilience, -connectedness, -flexibility).

This review (2020) examines the viability of microdosing psychedelics as a method to improve cognition and well-being. Available evidence indicates a variety of (perceived) benefits, including improvements in mood, focus, and creativity, with some people experiencing no discernible effects or expressing concerns about selective negative consequences like increased anxiety. However, most insights stem from observational studies using convenience samples that are biased or unrepresentative of the general population.